Convergent Calling: An Interview with Medtronic's Stephen Oesterle
Executive Summary
Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.
You may also be interested in...
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Building Medtronic Neuro by Trial: An Interview with Richard Kuntz, MD
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.